Leukaemia

Leukaemia constitutes a range of cancers, typically originating in the bone marrow, and resulting in overproduction of abnormal blood cells. It is a common condition, with

...


Read more on Leukaemia

 

 

Latest news articles

Added 9 days ago Drug news

Imbruvica + rituximab combination filed at FDA to treat younger patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). AbbVie

AbbVie announced it has submitted a supplemental New Drug Application (sNDA) to the FDA for Imbruvica (ibrutinib) in combination with...

Added 9 days ago Drug news

Teva + Celltrion announce the availability of Truxima Injection, the first biosimilar to Rituxan in the United States-

Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd, Celltrion, Inc., and Celltrion Healthcare, Co., Ltd.announced that...

Added 16 days ago Drug news

Phase III ADMIRAL trial data for Xospata in Acute Myeloid Leukemia published in NEJM.- Astellas

The New England Journal of Medicine has published detailed results from the Phase III ADMIRAL trial, which found that Astellas...

Search all news articles for Leukaemia
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars Knowledge Centre

Biosimilars Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more

Guidelines

End of life care for infants, children and young people with life-limiting conditions: planning and management

This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0–17 years) with life-limiting conditions. It aims to involve children, young people and their families...

Added 2 months ago

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The prevalence of chronic myeloid leukaemia is steadily rising due to the substantial prolongation of survival that has been achieved with targeted therapy. These updated guidelines on chronic myeloid leukaemia...

Added 7 years ago

ESMO Consensus Conference on Malignant Lymphoma: General Perspectives and Recommendations for Prognostic Tools in Mature B-cell Lymphomas and Chronic Lymphocytic Leukaemia

In order to complement the already available European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with malignant lymphomas, ESMO organised a consensus conference...

Added 3 years ago

Search all guidelines for Leukaemia
 

Journal articles

Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.

Areas covered: We review the biology and prognostic significance of FLT3 mutations in AML and discuss the pharmacology, clinical efficacy, and toxicity profile of gilteritinib. We also summarize important differences...

Added 2 hours ago

Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.

Internal tandem duplications and tyrosine kinase mutations in the fms-like tyrosine kinase 3 (FLT3) receptor can occur in acute myeloid leukemia (AML) and portend a poor prognosis.

Added 3 hours ago

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.

FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) remains as one of the most frequently mutated genes in acute myeloid leukemia (AML), especially in those with normal cytogenetics. The FLT3-ITD and FLT3-TKD...

Added 3 hours ago

Search all journal articles for Leukaemia
 

Clinical trials

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.

Added 1 month ago

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE)

This is a global, Phase 3b, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg bid in approximately 600 participants with chronic lymphocytic leukemia (CLL).

Added 1 month ago

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (CULMINATE)

The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy.

Added 1 month ago

Search all clinical trials for Leukaemia
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

CME

Treatment Optimisation in Chronic Lymphocytic Leukaemia

Treatment Optimisation in Chronic Lymphocytic Leukaemia
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Personalisation of chronic lymphocytic leukaemia (CLL) care

Personalisation of chronic lymphocytic leukaemia (CLL) care
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE
Search all CME for Leukaemia